Short summary: A prespecified analysis of the VESALIUS-CV trial found that evolocumab lowered LDL cholesterol and reduced major cardiovascular events in selected adults with high-risk diabetes. The study included people with features such as long diabetes duration, insulin use, microvascular disease, or qualifying atherosclerosis. It does not mean that everyone with diabetes should take evolocumab.
What was studied?
Evolocumab is a PCSK9 inhibitor that lowers LDL cholesterol. The VESALIUS-CV analysis looked at whether adding evolocumab could reduce a person’s first major cardiovascular event when they had diabetes or atherosclerosis but had not previously had a heart attack or stroke.
The analysis included adults with high-risk diabetes, qualifying atherosclerosis, or both. Participants had an LDL cholesterol level of at least 90 mg/dL (2.3 mmol/L) and were assigned to evolocumab 140 mg every two weeks or a matching placebo. The main analysis reported results for 6,002 people with high-risk diabetes.
High-risk diabetes in this study was defined using features such as microvascular disease, insulin use, or diabetes lasting at least 10 years. This is a more selected group than the broad population of people living with diabetes.
What did the trial find?
After 48 weeks, median LDL cholesterol was 47 mg/dL in the evolocumab group compared with 109 mg/dL in the placebo group. At baseline, 67% of the high-risk diabetes group was taking a high-intensity statin, and 24% was taking an SGLT2 inhibitor or GLP-1 receptor agonist.
Over a median follow-up of 4.6 years, evolocumab was associated with fewer major cardiovascular events:
- The three-part outcome of coronary heart disease death, heart attack, or ischaemic stroke was reduced by 29% relative to placebo. The hazard ratio was 0.71, with a 95% confidence interval of 0.59 to 0.86.
- When ischaemia-driven revascularisation was added to that outcome, the four-part outcome was reduced by 21%. The hazard ratio was 0.79, with a 95% confidence interval of 0.69 to 0.91.
- All-cause death occurred in 8.8% of people assigned to evolocumab and 11.0% of people assigned to placebo. The hazard ratio was 0.79, with a 95% confidence interval of 0.67 to 0.93.
The researchers reported that the findings were consistent whether or not participants had qualifying atherosclerosis and regardless of baseline LDL cholesterol, statin intensity, or use of an SGLT2 inhibitor or GLP-1 receptor agonist.
Why the population matters
These results are important, but the study did not test evolocumab in every person with diabetes. Participants had a high cardiovascular risk profile and an LDL cholesterol level meeting the trial criteria. People with shorter diabetes duration, lower LDL cholesterol, no additional high-risk features, or different medical conditions may have different expected benefits.
The findings also need to be understood alongside existing cholesterol treatment, overall cardiovascular risk, kidney function, other medicines, cost, access, and personal preferences. The trial was designed to answer a specific research question. It was not a treatment decision for an individual patient.
What does this mean for people with diabetes?
For some people with diabetes and high cardiovascular risk, the results add evidence that lowering LDL cholesterol with a PCSK9 inhibitor can reduce the chance of a first major cardiovascular event. Whether evolocumab is appropriate depends on the person’s LDL cholesterol, risk level, current treatment, ability to use an injectable medicine, and local prescribing guidance.
The result does not replace statins or other treatments that may be recommended for cardiovascular or kidney protection. It also does not mean that an LDL cholesterol target or medicine choice should be changed without a clinician’s review.
Questions to ask your diabetes or heart-care team
- What is my current LDL cholesterol and overall cardiovascular risk?
- Am I taking the recommended cholesterol treatment for my risk profile?
- Would a PCSK9 inhibitor add meaningful benefit in my situation?
- How would cost, injection technique, access, and follow-up affect this option?
- How should my cholesterol and other risk factors be monitored?
Do not start, stop, or change cholesterol or diabetes medicine because of a news article. Discuss decisions with the clinician who knows your medical history, kidney function, cholesterol results, cardiovascular risk, and current medicines.
Bottom line
In a selected group of adults with high-risk diabetes, evolocumab lowered LDL cholesterol and reduced major cardiovascular events over a median of 4.6 years. The results support a conversation about intensive cholesterol management for people who fit a similar high-risk profile. They are not a recommendation for every person with diabetes, and treatment decisions still need to be individualized.
Source and evidence summary
- Primary study: Prespecified analysis of the VESALIUS-CV randomized trial in adults with high-risk diabetes. PubMed PMID 42251764.
- Journal DOI: 10.2337/dc26-0847.
- Study design: Randomized, placebo-controlled analysis with a median follow-up of 4.6 years.